ORBACTIV Drug Patent Profile

When do Orbactiv patents expire, and when can generic versions of Orbactiv launch?

Orbactiv is a drug marketed by Melinta Therap and is included in one NDA. There are four patents protecting this drug.

This drug has forty-six patent family members in nineteen countries.

The generic ingredient in ORBACTIV is oritavancin diphosphate. One supplier is listed for this compound. Additional details are available on the oritavancin diphosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Orbactiv

Orbactiv was eligible for patent challenges on August 6, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 29, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ORBACTIV

International Patents:	46
US Patents:	4
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ORBACTIV

ORBACTIV is protected by four US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes			Y
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes
Melinta Therap	ORBACTIV	oritavancin diphosphate	POWDER;INTRAVENOUS	206334-001	Aug 6, 2014		RX	Yes	Yes

International Patents for ORBACTIV

When does loss-of-exclusivity occur for ORBACTIV?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Japan

Mexico

Netherlands

New Zealand

Norway

Poland

Portugal

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ORBACTIV around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	950374
World Intellectual Property Organization (WIPO)	2010025438
Russian Federation	2145609	DERIVATIVES OF GLYCOPEPTIDE OR THEIR SALTS, METHOD OF SYNTHESIS, PHARMACEUTICAL COMPOSITION
New Zealand	335840	Method for reductively alkylating glycopeptide antibiotics preferably A82846B (chloroorienticin A)
Germany	69532013
Canada	2736860	METHODES DE TRAITEMENT UTILISANT DES DOSES UNIQUES D'ORITAVANCINE (METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN)
Austria	349464

Supplementary Protection Certificates for ORBACTIV

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2337575	41/2016	Austria		PRODUCT NAME: ORITAVANCIN UND DESSEN PHARMAZEUTISCHE SALZE; REGISTRATION NO/DATE: EU/1/15/989 (MITTEILUNG) 20150323
2337575	132016000101430	Italy		PRODUCT NAME: ORITAVANCINA E I SUOI SALI DI ADDIZIONE FARMACEUTICAMENTE ACCETTABILI, IN PARTICOLARE IL DIFOSFATO(ORBACTIV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/989, 20150323
2337575	C20160037	Finland		PRODUCT NAME: MIGALASTAAT;REG NO/DATE: EU/1/15/1082 31.05.2016
2337575	CA 2016 00044	Denmark		PRODUCT NAME: ORITAVANCIN OG/ELLER FARMACEUTISKE SALTE HERAF, HERUNDER DIFOSFATSALTE; REG. NO/DATE: EU/1/15/989 20150323
2337575	1690041-7	Sweden		PRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; FIRST MARKETING AUTHORIZATION NUMBER SE: EU/1/15/989, 2015-03-23
2337575	122016000075	Germany		PRODUCT NAME: ORITAVANCIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/989 20150319
2337575	2016019	Norway		PRODUCT NAME: ORITAVANCIN OG FARMASOEYTISK; REG. NO/DATE: EU/1/15/989 20150415

Investment Scenario and Fundamentals Analysis for ORBACTIV

Last updated: February 20, 2026

What is ORBACTIV?

ORBACTIV (oritavancin) is an antibiotic approved by the U.S. Food and Drug Administration (FDA) in August 2014. It is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) [1].

Market Overview and Revenue Potential

ORBACTIV targets the ABSSSI segment, valued at approximately $2.2 billion globally in 2022. The drug's once-weekly dosing improves outpatient treatment compliance. The U.S. represents roughly 60% of the global market, with potential expansion into hospital-administered intravenous (IV) formulations for complicated infections.

Commercial Performance and Market Share

• U.S. sales in 2022: Estimated at $120 million, reflecting moderate market penetration.
• Share: Estimated at 8-10% of the specific ABSSSI segment, indicating growth potential with increased awareness and physician adoption.

Competitive Landscape

ORBACTIV faces competition from drugs like dalbavancin (Dalvance), linezolid (Zyvox), and vancomycin. Dalbavancin, similar in dosing frequency, holds a larger share due to earlier market entry and broader approval indications.

Competitor	Market Penetration (2022)	Dosing Schedule	Approved Indications
ORBACTIV	8-10%	Once weekly	ABSSSI, off-label use in endocarditis
Dalvance	15%	Once weekly	ABSSSI, hospital-acquired pneumonia
Zyvox (linezolid)	20%	Daily oral/IV	MRSA, VRE, pneumonia

Regulatory and Development Pipeline

• FDA Approval: For ABSSSI, with ongoing discussions about expanding indications.
• Pipeline: ORBACTIV is under investigation for use in osteomyelitis and endocarditis, potentially broadening its market.

Manufacturing and Pricing Strategy

• Price point: Approximate wholesale cost in the U.S. $3,000 per dose.
• Reimbursement: Covered widely by Medicare and private insurers, though outpatient administration costs influence adoption.

Financial Outlook and Investment Considerations

• Revenue growth hinges on increasing market share within ABSSSI and penetration into hospital settings.
• The company has invested in expanding indications, which could double or triple sales if approved.
• Patent life extends to 2032, before generic competition is expected.

Risks and Challenges

• Competition from established antibiotics may hinder rapid growth.
• Limited approval for indications beyond ABSSSI constrains revenue.
• Price sensitivity and reimbursement policies could impact profitability.

Key Metrics for Investment Evaluation

Metric	Value/Estimate	Source
Annual sales (2022)	~$120 million	Analyst estimates
Market share (2022)	8-10%	Industry reports
Patent expiration	2032	Patent filings
Development pipeline approvals	Pending for osteomyelitis/endocarditis	Company disclosures

Key Takeaways

• ORBACTIV operates in a competitive niche within antibiotics, with limited but steady current sales.
• Its once-weekly dosing offers a competitive advantage in outpatient settings.
• Market expansion depends on indication approvals and physician adoption.
• Revenue growth potential remains contingent on pipeline success and competitive dynamics.
• Price and reimbursement policies influence market penetration and profitability.

FAQs

1. How does ORBACTIV compare price-wise to competitors?
It costs approximately $3,000 per dose, similar to dalbavancin, but less than some alternative therapies like linezolid.

2. What is the approval outlook for expanded indications?
Ongoing trials for osteomyelitis and endocarditis could lead to additional approvals, potentially doubling sales.

3. How resistant are bacteria to ORBACTIV?
Limited resistance data exist; however, it is effective against resistant strains like MRSA, which constitutes a primary target.

4. What is the key regulatory risk?
Failure to gain approval for additional indications could limit growth and valuation.

5. Is patent protection sufficient for long-term exclusivity?
Yes, patents expire in 2032, providing over a decade of market exclusivity barring generic entry.

References

[1] FDA. (2014). FDA approves new antibiotic for complicated skin infections. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-complicated-skin-infections